Google
COGT — COGENT BIOSCIENCES INC (Healthcare >> Biotechnology)
COGT FAQ
What is COGT's ROE?
COGENT BIOSCIENCES INC reports a Return on Equity (ROE) of -58.30%.
What is COGT's dividend yield?
COGENT BIOSCIENCES INC offers a dividend yield of 0.00%.
What is COGT's Deepscope Quality Score?
Deepscope rates COGT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy COGT?
Deepscope's AI Timing Score for COGT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does COGT belong to?
COGENT BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 31.16
Price
0.82
(2.63%)
Day Change
|
|
|---|
COGT, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 31.16 |
| PBV / Sector |
8.72 / 4.75
|
| Earning Per Share | -2.08 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
75.44 M
|
| Average 1W Daily Value |
69.15 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:07 |
| Symbol | COGT |
| Name | COGENT BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 170.87 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,300.33 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 275 Wyman Street, Waltham, MA, United States, 02451
Phone: 617 945 5576
Website: https://www.cogentbio.com
Employees: 258
Sector: Healthcare >> Biotechnology
Description: Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
